FindTrial
Sign In

To study the efficacy of low dose oral minoxidil versus 5% topical minoxidil versus 5% topical minoxidil and Platelet rich plasma procedure combination in patients with androgenetic alopecia

A randomised three-armed comparative trial to study the efficacy of low dose oral minoxidil 2.5mg once daily versus 5% topical minoxidil twice daily versus 5% topical minoxidil twice daily +PRP combination in patients with androgenetic alopecia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052909
Enrollment
60
Registered
2023-05-19
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L648- Other androgenic alopecia

Interventions

Intervention1: Oral minoxidil: Low dose oral minoxidil 2.5mg once daily in androgenetic alopecia Intervention2: Topical minoxidil 5%: Topical minoxidil 5% given twice daily in androgenetic alopecia In

Sponsors

Self
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All androgenetic alopecia patients from Norwood Hamilton grade 3-5 are recruited.

Exclusion criteria

Exclusion criteria: Patients suffering from other hair disorders, hypotensive episodes, irritant dermatitis to minoxidil, keloidal tendency and bleeding disorders

Design outcomes

Primary

MeasureTime frame
Proportion of patients showing improvement in modified Norwood-Hamilton scale by 1 grade in each group at end of 24 weeksTimepoint: assessed at baseline, 4th month, 6th month—

Secondary

MeasureTime frame
Videodermoscopic assessment as proportion of patients showing 25% increase in hair density 25% decrease in hair diameter diversity and 25% decrease in number of vellus hair/mm2 by end of 24 weeks. Change in population of natural (CD25 high) and induced (CD25 low) T reg cells using Fluorescent activated cell sorting change in NOTCH pathway jagged 1 SOX 9 expression in hair follicle using immunofluorescence pre and post treatmentTimepoint: assessment done at baseline, 16 weeks and 24 weeks—

Countries

India

Contacts

Public ContactJanaani P

Postgraduate institute of medical education and research

drsen_2000@yahoo.com09384337014

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026